| Fund ID | 805-3847972073 |
| Fund type | Venture Capital Fund |
| 3(c)(1) exclusion | Yes |
| 3(c)(7) exclusion | No |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| Sales limited to qualified investors | Yes |
| % of assets independently valued | 94% |
| Owned by the adviser or related persons | 5% |
| Owned by funds of funds | 15% |
| Owned by non-U.S. persons | 50% |
| Fund | Type | Gross assets |
|---|---|---|
| Redco II Master Fund, L.P. | Hedge | $1.59B |
| Redmile Biopharma Investments III, L.P. | Private Equity | $972.2M |
| Redmile Capital Offshore II Master Fund, Ltd. | Hedge | $845.8M |
Redmile Biopharma Investments I, L.P. reports $150 million in gross assets, among the top 35% of private funds by size.
The stated minimum investment is $2 million.
Redmile Biopharma Investments I, L.P. is managed by Redmile Group, LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.